» Articles » PMID: 17975120

Serum Total Bilirubin Level and Prevalent Lower-extremity Peripheral Arterial Disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004

Overview
Date 2007 Nov 3
PMID 17975120
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bilirubin, with recently recognized antioxidant and antiinflammatory activity, has emerged as a candidate for atheroprotection. We hypothesized that higher levels of bilirubin would reduce susceptibility to peripheral arterial disease (PAD).

Methods And Results: We analyzed 7075 adults with data available on the ankle brachial index, serum total bilirubin level, and PAD risk factors in the National Health and Nutrition Examination Survey (1999 to 2004), a nationally representative cross-sectional examination of the United States population. A 0.1 mg/dL increase in bilirubin level was associated with a 6% reduction in the odds of PAD (OR 0.94 [95% CI 0.90 to 0.98]) after adjustment for age, gender, race/ethnicity, smoking status, diabetes, hypertension, hypercholesterolemia, chronic kidney disease, CRP, and homocysteine. This result was not dependent on bilirubin levels above the reference range, liver disease, or alcohol intake. The inverse association of bilirubin with PAD tended to be stronger among men (OR 0.90 [95% CI 0.85 to 0.96]) compared with women (OR 0.97 [95% CI 0.91 to 1.04]; P(interaction)=0.05), and was stronger among active smokers (OR 0.81 [95% CI 0.73 to 0.90]) compared with nonsmokers (OR 0.97 [95% CI 0.93 to 1.02]; P(interaction)<0.01).

Conclusions: Increased serum total bilirubin level is associated with reduced PAD prevalence. This result is consistent with the hypothesis that bilirubin is protective from PAD.

Citing Articles

Association of elevated baseline bilirubin caused by preadmission statin use with cardiovascular prognosis in patients undergoing elective percutaneous coronary intervention.

Zhu Y, Li D, Li J, Wang Y, Chen Z, Lv Q Sci Rep. 2024; 14(1):20451.

PMID: 39227723 PMC: 11371819. DOI: 10.1038/s41598-024-71497-x.


The Metabolic Characteristics of Patients at the Risk for Diabetic Foot Ulcer: A Comparative Study of Diabetic Patients with and without Diabetic Foot.

Li X, Wen S, Dong M, Yuan Y, Gong M, Wang C Diabetes Metab Syndr Obes. 2023; 16:3197-3211.

PMID: 37867628 PMC: 10590077. DOI: 10.2147/DMSO.S430426.


Genetics of Plasma Bilirubin and Associations between Bilirubin and Cardiometabolic Risk Profiles in Danish Children and Adolescents.

Ullah A, Stankevic E, Holm L, Stinson S, Juel H, Fonvig C Antioxidants (Basel). 2023; 12(8).

PMID: 37627608 PMC: 10451688. DOI: 10.3390/antiox12081613.


Atazanavir-induced unconjugated hyperbilirubinemia prevents vascular hyporeactivity during experimental human endotoxemia.

Dorresteijn M, Dekker D, Zwaag J, Heemskerk S, Roelofs H, Smits P Front Immunol. 2023; 14:1176775.

PMID: 37261364 PMC: 10228648. DOI: 10.3389/fimmu.2023.1176775.


High-normal serum bilirubin decreased the risk of lower limb atherosclerosis in type 2 diabetes: a real-world study.

Zhao C, Wang J, Chen M, Ke J, Li M, Li L Diabetol Metab Syndr. 2023; 15(1):105.

PMID: 37208703 PMC: 10197852. DOI: 10.1186/s13098-023-01088-9.